Oculis (NASDAQ:OCS – Get Free Report) and Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Oculis and Terns Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oculis | 0 | 0 | 5 | 0 | 3.00 |
| Terns Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
Oculis currently has a consensus target price of $29.20, indicating a potential upside of 84.69%. Terns Pharmaceuticals has a consensus target price of $15.90, indicating a potential upside of 112.00%. Given Terns Pharmaceuticals’ higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Oculis.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Oculis | -7,679.05% | -61.33% | -49.91% |
| Terns Pharmaceuticals | N/A | -39.58% | -37.69% |
Earnings & Valuation
This table compares Oculis and Terns Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oculis | $980,000.00 | 653.44 | -$98.92 million | ($1.78) | -8.88 |
| Terns Pharmaceuticals | $1.00 million | 485.08 | -$90.21 million | ($1.26) | -5.95 |
Terns Pharmaceuticals has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Oculis has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500.
Institutional & Insider Ownership
22.3% of Oculis shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Terns Pharmaceuticals beats Oculis on 10 of the 14 factors compared between the two stocks.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
